AUT 00206

Drug Profile

AUT 00206

Alternative Names: AUT00206

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Autifony Therapeutics; University of Manchester; University of Newcastle upon Tyne
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Shaw potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia
  • Preclinical Fragile X syndrome

Most Recent Events

  • 18 Dec 2017 Autifony Therapeutics and Boehringer Ingelheim enter an option agreement for Shaw potassium channel modulators, including AUT 00206
  • 01 Nov 2017 Autifony Therapeutics completes a phase Ib trial in Healthy volunteers in United Kingdom (PO) (NCT02935725)
  • 10 Jul 2017 Updated adverse events data from phase I trial in healthy volunteers released by Autifony Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top